Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Simmons Bank

Simmons Bank lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,706 shares of the biopharmaceutical company’s stock after selling 4,455 shares during the quarter. Simmons Bank’s holdings in Bristol-Myers Squibb were worth $2,345,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $25,000. Milestone Investment Advisors LLC acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded up $0.14 during midday trading on Tuesday, reaching $44.04. The company’s stock had a trading volume of 10,924,172 shares, compared to its average volume of 15,784,603. Bristol-Myers Squibb has a fifty-two week low of $43.33 and a fifty-two week high of $69.10. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock’s 50 day simple moving average is $50.11 and its 200 day simple moving average is $50.48. The firm has a market capitalization of $89.27 billion, a PE ratio of -14.21, a P/E/G ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.05 earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.45%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.